retatrutide phase 2 results weight loss NEJM Trial: 48-Week Explained – Bolt Pharmacy Retatrutide, a GIP, GLP-1 and

Designed to assist with weight management and metabolic health

Importantly, this report was authored by health practitioners affiliated with a clinic selling BPC-157 injections, so theres a clear conflict of interest

Saxenda is a once-daily injection

64.7% of Respondents Reported Eventually Quitting GLP-1s 64.7% of participants in our study reported eventually quitting the use of GLP-1 medications

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome

99 These findings largely mirror results from a separate independent analysis of the same patients in the TriNetX database, 100 with both studies suggesting a reduction in rates of mortality with use of GLP-1 medicines